OMEICOS Therapeutics develops therapeutics for the prevention and treatment of cardiovascular diseases. It also offers its therapeutic services for the treatment in inflammatory, cardiovascular, ophthalmology, and other disease indications. Its therapeutic strategy is based upon the discovery of natural CYP-P450 generated metabolites of omega-3 fatty acids, so called epoxyeicosanoids. This new class of bioactive lipid mediators activates type specific cellular endogenous pathways that can be therapeutically deployed in inflammatory, cardiovascular, and other diseases.
|Employees (est.) (May 2019)||14||(+8%)|
OMEICOS Therapeutics total Funding
OMEICOS Therapeutics latest funding size
Time since last funding
|7 months ago|
OMEICOS Therapeutics investors
|High-Tech Gruenderfonds, KfW Bankengruppe, KFW, Vesalius Biocapital Partners, IBB Beteiligungsgesellschaft, VC Fonds Technologie Berlin, Remiges Ventures, The Falck Revocable Trust, Ascenion GmbH, KFW Group, SMSgroup, High-Tech Gründerfonds, Forbion, Vesalius Biocapital, Remiges BioPharma Fund, SMS Group, VC Fonds Technologie Berlin|
OMEICOS Therapeutics has 71 Twitter Followers. The number of followers has increased 5% month over month and increased 15.3% quarter over quarter
Tweets last 30 days
Avg. likes per Tweet
Tweets with engagement
When was OMEICOS Therapeutics founded?
OMEICOS Therapeutics was founded in 2013.
Who are OMEICOS Therapeutics key executives?
OMEICOS Therapeutics's key executives are Robert Fischer, Karen Uhlmann and Luciana Summo.
How many employees does OMEICOS Therapeutics have?
OMEICOS Therapeutics has 14 employees.
Who are OMEICOS Therapeutics competitors?
Competitors of OMEICOS Therapeutics include Otonomy, Biogen and Shire.
Where is OMEICOS Therapeutics headquarters?
OMEICOS Therapeutics headquarters is located at 10 Robert-Rössle-Straße, Berlin.
Where are OMEICOS Therapeutics offices?
OMEICOS Therapeutics has offices in Berlin and Cambridge.
How many offices does OMEICOS Therapeutics have?
OMEICOS Therapeutics has 2 offices.